Onderzoeker
Robert Paridaens
- Disciplines:Laboratoriumgeneeskunde, Palliatieve zorg en zorg rond het levenseinde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Verpleegkunde, Andere paramedische wetenschappen, Andere translationele wetenschappen, Andere medische en gezondheidswetenschappen
Affiliaties
- Laboratorium Experimentele Oncologie (Afdeling)
Lid
Vanaf1 okt 2005 → 30 sep 2017
Publicaties
21 - 30 van 124
- VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis(2014)
Auteurs: Benoit Beuselinck, Diether Lambrechts, Joost Berkers, Hendrik Van Poppel, Robert Paridaens, Patrick Schöffski, Evelyne Lerut
Pagina's: 103 - 12 - Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors(2014)
Auteurs: Robert Paridaens, Anne-Sophie Dieudonné, Sigrid Hatse, Patrick Neven, Diether Lambrechts, Hans Wildiers
Pagina's: 201 - MicroRNA Related Polymorphisms and Breast Cancer Risk(2014)
Auteurs: Diether Lambrechts, Matthieu Moisse, Robert Paridaens, Rose Christiaens
- The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen(2014)
Auteurs: Diether Lambrechts, Dirk Smeets, Ann Belmans, Hans Wildiers, Robert Paridaens, Dirk Timmerman, Rose Christiaens, Ignace Vergote, Patrick Neven
Pagina's: 90 - 5 - Triple negative breast cancer: Clinical characteristics in the different histological subtypes(2013)
Auteurs: Ann Smeets, Kathleen Forceville, Barbara Brouwers, Patrick Neven, Philippe Moerman, Ben Van Calster, Rose Christiaens, Robert Paridaens, Hans Wildiers
Pagina's: 761 - 6 - Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial(2013)
Auteurs: Robert Paridaens
Pagina's: 190 - 196 - Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis(2013)
Auteurs: Robert Paridaens
Pagina's: 2257 - U59 - Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice(2013)
Auteurs: Ann Smeets, Annouschka Laenen, Chantal Van Ongeval, Philippe Moerman, Robert Paridaens, Hans Wildiers, Patrick Neven, Rose Christiaens
Pagina's: 357 - 61 - Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)(2013)
Auteurs: Diether Lambrechts, Anne-Sophie Dieudonné, Sigrid Hatse, Barbara Brouwers, Patrick Neven, Ann Belmans, Patrick Schöffski, Robert Paridaens, Hans Wildiers
Pagina's: 1513 - 1525 - Circulating CCL5 Levels in Patients with Breast Cancer: Is There a Correlation with Lymph Node Metastasis?(2013)
Auteurs: Ann Smeets, Barbara Brouwers, Sigrid Hatse, Annouschka Laenen, Robert Paridaens, Beppe Floris, Hans Wildiers, Rose Christiaens